23 Feb Tenaya Therapeutics
Faraz Ali, CEO
Oct. 6 | 12:00pm | FLW Ballroom G
South San Francisco, CA
(NASDAQ: TNYA)
Tenaya Therapeutics is a clinical-stage biotechnology company committed to a bold mission: to discover, develop and deliver potentially curative therapies that address the underlying drivers of heart disease. Tenaya’s is focused on advancing its two lead gene therapy candidates, TN-201 for MYBPC3-associated hypertrophic cardiomyopathy (HCM) and TN-401 for PKP2-associated arrhythmogenic right ventricular cardiomyopathy (ARVC). A third clinical-stage candidate, TN-301, a small molecule HDAC6 inhibitor intended for heart failure with preserved ejection fraction (HFpEF), and multiple early-stage programs in preclinical development were discovered internally. Tenaya has employed a suite of integrated internal capabilities, including modality agnostic target validation, capsid engineering and manufacturing, to generate its portfolio of genetic medicines aimed at the treatment of both rare genetic disorders and more prevalent heart conditions.
